DeepMed Research

Suzhou Transcenta Therapeutics Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3

Not yet recruiting

Conditions: Gastric Cancer
Gastroesophageal-junction Cancer
Advanced Cancer

Interventions: Drug: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
Drug: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 950

Registration Number: NCT06093425

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Phase 1

Active, not recruiting

Conditions: Locally Advanced Solid Tumor
Metastatic Tumor
Colorectal Adenocarcinoma

Interventions: Drug: TST003

First Posted Date: 2023-02-16

Last Posted Date: 2024-10-18

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 111

Registration Number: NCT05731271

Locations: 🇺🇸
OHSU, Portland, Oregon, United States
🇺🇸
Mary Crowley, Dallas, Texas, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Locally Advanced or Metastatic Cancers
Metastatic Human Papillomavirus-Related Malignant Neoplasm

Interventions: Drug: TST005

First Posted Date: 2021-07-12

Last Posted Date: 2023-10-23

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT04958434

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Cancer

Interventions: Drug: TST001
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Capecitabine
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2020-07-31

Last Posted Date: 2024-10-21

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 320

Registration Number: NCT04495296

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 37 locations

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Cancer
Gastric Cancer
Gastroesophageal-junction Cancer
Pancreatic Cancer

Interventions: Drug: TST001
Drug: Nivolumab Injection [Opdivo]
Drug: Gemcitabine
Drug: mFOLFOX6
Drug: Albumin-Bound Paclitaxel

First Posted Date: 2020-05-21

Last Posted Date: 2025-04-13

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT04396821

Locations: 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 15 locations

A Study of MSB0254 Injection in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: MSB0254 Injection

First Posted Date: 2020-05-08

Last Posted Date: 2023-04-05

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 25

Registration Number: NCT04381325

Locations: 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
FuDan University ZhongShan Hospital, Shanghai, China

A Study of MSB2311 in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: 10 mg/kg Q2W
Drug: 20 mg/kg Q3W

First Posted Date: 2020-02-17

Last Posted Date: 2023-12-18

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT04272944

Locations: 🇨🇳
Mabspace Biosciences (Suzhou) Co., Ltd., Suzhou, Jiangsu, China

A Phase I Study of MSB2311 in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: 3 mg/kg Q3W MSB2311 Injection
Drug: 10 mg/kg Q2W MSB2311 Injection
Drug: 10 mg/kg Q3W MSB2311 Injection
Drug: 20 mg/kg Q3W MSB2311 Injection

First Posted Date: 2018-03-13

Last Posted Date: 2023-12-18

Lead Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT03463473

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy